Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AIM Vaccine Co's share price for the quarter that ended in Dec. 2023 was HK$7.85. AIM Vaccine Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 1,211 Mil. Therefore, AIM Vaccine Co's market cap for the quarter that ended in Dec. 2023 was HK$9,507 Mil.
AIM Vaccine Co's quarterly market cap
increased
from Dec. 2022 (HK$28,823 Mil) to Jun. 2023 (HK$54,316 Mil) but then
declined
from Jun. 2023 (HK$54,316 Mil) to Dec. 2023 (HK$9,507 Mil).
AIM Vaccine Co's annual market cap
increased
from Dec. 2021 (HK$0 Mil) to Dec. 2022 (HK$28,823 Mil) but then
declined
from Dec. 2022 (HK$28,823 Mil) to Dec. 2023 (HK$9,507 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AIM Vaccine Co's Enterprise Value for Today is HK$9,739 Mil.
AIM Vaccine Co Market Cap Historical Data
The historical data trend for AIM Vaccine Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AIM Vaccine Co's Market Cap
For the Biotechnology subindustry, AIM Vaccine Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM Vaccine Co's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's Market Cap distribution charts can be found below:
* The bar in red indicates where AIM Vaccine Co's Market Cap falls into.
AIM Vaccine Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AIM Vaccine Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co (HKSE:06660) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AIM Vaccine Co Market Cap Related Terms
Thank you for viewing the detailed overview of AIM Vaccine Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development, manufacturing and commercialization. The products available for sale mainly include Recombinant HBV vaccine, Human rabies vaccine, HFRS Vaccine, hepatitis A vaccine (human diploid cell), Group A, C, Y and W135 MPSV, mumps vaccine, freeze-dried human rabies vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine. Geographically, the company generates all of its revenues in the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06660 has been successfully added to your